These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

902 related items for PubMed ID: 18957615

  • 41. Insulin, somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features.
    Morales AJ, Laughlin GA, Bützow T, Maheshwari H, Baumann G, Yen SS.
    J Clin Endocrinol Metab; 1996 Aug; 81(8):2854-64. PubMed ID: 8768842
    [Abstract] [Full Text] [Related]

  • 42. Hormonal profile in women with polycystic ovarian syndrome with or without type 1 diabetes mellitus.
    Codner E, Iñíguez G, Villarroel C, Lopez P, Soto N, Sir-Petermann T, Cassorla F, Rey RA.
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4742-6. PubMed ID: 17895317
    [Abstract] [Full Text] [Related]

  • 43. Phenotypic variation in anti-Mullerian hormone (AMH) production per follicle in women with polycystic ovary syndrome (PCOS) and isolated polycystic ovarian morphology (PCOM): an observational cross-sectional study.
    Bhide P, Kulkarni A, Dilgil M, Dhir P, Shah A, Gudi A, Homburg R.
    Gynecol Endocrinol; 2017 Oct; 33(10):801-806. PubMed ID: 28454499
    [Abstract] [Full Text] [Related]

  • 44. Relative importance of AMH and androgens changes with aging among non-obese women with polycystic ovary syndrome.
    Kushnir VA, Halevy N, Barad DH, Albertini DF, Gleicher N.
    J Ovarian Res; 2015 Jul 09; 8():45. PubMed ID: 26156856
    [Abstract] [Full Text] [Related]

  • 45. Ovarian morphology assessed by magnetic resonance imaging in women with and without polycystic ovary syndrome and associations with antimüllerian hormone, free testosterone, and glucose disposal rate.
    Leonhardt H, Hellström M, Gull B, Lind AK, Nilsson L, Janson PO, Stener-Victorin E.
    Fertil Steril; 2014 Jun 09; 101(6):1747-56.e1-3. PubMed ID: 24661732
    [Abstract] [Full Text] [Related]

  • 46. The metabolic status modulates the effect of metformin on the antimullerian hormone-androgens-insulin interplay in obese women with polycystic ovary syndrome.
    Romualdi D, De Cicco S, Tagliaferri V, Proto C, Lanzone A, Guido M.
    J Clin Endocrinol Metab; 2011 May 09; 96(5):E821-4. PubMed ID: 21307134
    [Abstract] [Full Text] [Related]

  • 47. Relationship between anti-Müllerian hormone (AMH) and insulin levels during different tanner stages in daughters of women with polycystic ovary syndrome.
    Sir-Petermann T, Ladrón de Guevara A, Codner E, Preisler J, Crisosto N, Echiburú B, Maliqueo M, Sánchez F, Perez-Bravo F, Cassorla F.
    Reprod Sci; 2012 Apr 09; 19(4):383-90. PubMed ID: 22344736
    [Abstract] [Full Text] [Related]

  • 48. Müllerian-inhibiting substance reflects ovarian findings in women with polycystic ovary syndrome better than does inhibin B.
    Chu MC, Carmina E, Wang J, Lobo RA.
    Fertil Steril; 2005 Dec 09; 84(6):1685-8. PubMed ID: 16359965
    [Abstract] [Full Text] [Related]

  • 49. The role of anti-Müllerian hormone in the pathogenesis and pathophysiological characteristics of polycystic ovary syndrome.
    Qi X, Pang Y, Qiao J.
    Eur J Obstet Gynecol Reprod Biol; 2016 Apr 09; 199():82-7. PubMed ID: 26914398
    [Abstract] [Full Text] [Related]

  • 50. Neuropeptide Y, leptin, galanin and insulin in women with polycystic ovary syndrome.
    Baranowska B, Radzikowska M, Wasilewska-Dziubińska E, Kapliński A, Roguski K, Płonowski A.
    Gynecol Endocrinol; 1999 Oct 09; 13(5):344-51. PubMed ID: 10599552
    [Abstract] [Full Text] [Related]

  • 51. Use of the serum anti-Müllerian hormone assay as a surrogate for polycystic ovarian morphology: impact on diagnosis and phenotypic classification of polycystic ovary syndrome.
    Fraissinet A, Robin G, Pigny P, Lefebvre T, Catteau-Jonard S, Dewailly D.
    Hum Reprod; 2017 Aug 01; 32(8):1716-1722. PubMed ID: 28854589
    [Abstract] [Full Text] [Related]

  • 52. Features of polycystic ovary syndrome (PCOS) in women with functional hypothalamic amenorrhea (FHA) may be reversible with recovery of menstrual function.
    Carmina E, Fruzzetti F, Lobo RA.
    Gynecol Endocrinol; 2018 Apr 01; 34(4):301-304. PubMed ID: 29073797
    [Abstract] [Full Text] [Related]

  • 53. [Anti-Müllerian hormone as an indicator of reproductive health in women with obesity and concomitant polycystic ovary syndrome].
    Durmanova AK, Otarbaev NK.
    Ter Arkh; 2016 Apr 01; 88(12):41-44. PubMed ID: 28139558
    [Abstract] [Full Text] [Related]

  • 54. Reproductive and metabolic determinants of granulosa cell dysfunction in normal-weight women with polycystic ovary syndrome.
    Guedikian AA, Lee AY, Grogan TR, Abbott DH, Largaespada K, Chazenbalk GD, Dumesic DA.
    Fertil Steril; 2018 Mar 01; 109(3):508-515. PubMed ID: 29428312
    [Abstract] [Full Text] [Related]

  • 55. Atherogenic metabolic profile in PCOS patients: role of obesity and hyperandrogenism.
    Castelo-Branco C, Steinvarcel F, Osorio A, Ros C, Balasch J.
    Gynecol Endocrinol; 2010 Oct 01; 26(10):736-42. PubMed ID: 20569105
    [Abstract] [Full Text] [Related]

  • 56. Polycystic Ovary-Like Abnormalities (PCO-L) in women with functional hypothalamic amenorrhea.
    Robin G, Gallo C, Catteau-Jonard S, Lefebvre-Maunoury C, Pigny P, Duhamel A, Dewailly D.
    J Clin Endocrinol Metab; 2012 Nov 01; 97(11):4236-43. PubMed ID: 22948766
    [Abstract] [Full Text] [Related]

  • 57. Hormone profiling, including anti-Müllerian hormone (AMH), for the diagnosis of polycystic ovary syndrome (PCOS) and characterization of PCOS phenotypes.
    Sova H, Unkila-Kallio L, Tiitinen A, Hippeläinen M, Perheentupa A, Tinkanen H, Puukka K, Bloigu R, Piltonen T, Tapanainen JS, Morin-Papunen L.
    Gynecol Endocrinol; 2019 Jul 01; 35(7):595-600. PubMed ID: 30668196
    [Abstract] [Full Text] [Related]

  • 58. Ovarian morphology as a predictor of hormonal values in polycystic ovary syndrome.
    van der Westhuizen S, van der Spuy ZM.
    Ultrasound Obstet Gynecol; 1996 May 01; 7(5):335-41. PubMed ID: 8774098
    [Abstract] [Full Text] [Related]

  • 59. Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome.
    Gambineri A, Patton L, De Iasio R, Palladoro F, Pagotto U, Pasquali R.
    J Clin Endocrinol Metab; 2007 Jun 01; 92(6):2066-73. PubMed ID: 17356050
    [Abstract] [Full Text] [Related]

  • 60. Obesity and inflammatory biomarkers in women with polycystic ovary syndrome.
    Shen SH, Shen SY, Liou TH, Hsu MI, Chang YC, Cheng CY, Hsu CS, Tzeng CR.
    Eur J Obstet Gynecol Reprod Biol; 2015 Sep 01; 192():66-71. PubMed ID: 26177495
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 46.